Inosine Pranobex: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (2)29%

Mortality (1)46%

RCTs (1)27%

Early (2)29%

00.511.5+

← Inosine
Pranobex
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Inosine pranobex COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Jayanthi (DB RCT)27%0.73 · 0.59–0.90no recov.79/204112/210 Veselý46%0.54 · 0.25–1.16deathpopulation-based cohort

Early treatment29%0.71 · 0.58–0.8779/204112/21029% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0012

All studies29%0.71 · 0.58–0.8779/204112/21029% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.001200.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Veselý46%0.54 · 0.25–1.16population-based cohort

Early treatment46%0.54 · 0.25–1.1646% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.11

All studies46%0.54 · 0.25–1.1646% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.1100.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Veselý46%0.54 · 0.25–1.16deathpopulation-based cohort

Early treatment46%0.54 · 0.25–1.1646% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.11

All studies46%0.54 · 0.25–1.1646% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.1100.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Jayanthi (DB RCT)27%0.73 · 0.59–0.90no recov.79/204112/210

Early treatment27%0.73 · 0.59–0.9079/204112/21027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0034

All studies27%0.73 · 0.59–0.9079/204112/21027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.003400.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Jayanthi (DB RCT)27%0.73 · 0.59–0.90no recov.79/204112/210

Early treatment27%0.73 · 0.59–0.9079/204112/21027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0034

All studies27%0.73 · 0.59–0.9079/204112/21027% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.003400.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Jayanthi (DB RCT)27%0.73 · 0.59–0.90no recov.79/204112/210 Veselý46%0.54 · 0.25–1.16deathpopulation-based cohort

Early treatment29%0.71 · 0.58–0.8779/204112/21029% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.0012

All studies29%0.71 · 0.58–0.8779/204112/21029% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.001200.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →

c19early.org

October 2026

Inosine pranobex COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Jayanthi (DB RCT)27%0.73 · 0.59–0.90no recov.79/204112/210 Jayanthi (DB RCT)6%0.94 · 0.41–2.16no recov.10/20411/210 Jayanthi (DB RCT)33%0.67 · 0.54–0.84no improv.72/204110/210 Jayanthi (DB RCT)−14%1.14 · 0.47–2.76no improv.10/2049/210 Veselý46%0.54 · 0.25–1.16deathpopulation-based cohort Veselý22%0.78 · 0.71–0.85deathpopulation-based cohort Veselý65%0.35 · 0.24–0.51death

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Inosine Pranobex
reduces riskInosine Pranobex
increases risk →